Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 28, 2013
Słowa kluczowe:
program lekowy, NDRP, pemetreksed, erlotynib, gefitynib, docetaksel
##plugins.themes.bootstrap3.article.main##
Abstrakt
W artykule przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca wobec ustaleń aktualnie obowiązującego programu lekowego.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.generic.paperbuzz.metrics##
##plugins.generic.paperbuzz.loading##
##plugins.themes.bootstrap3.article.details##
Jak cytować
1.
Kowalski DM, Krawczyk P. Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego. OncoReview [Internet]. 28 czerwiec 2013 [cytowane 23 listopad 2024];3(2(10):95-101. Dostępne na: https://journalsmededu.pl/index.php/OncoReview/article/view/335
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Pignon J.P., Tribodet H., Scagliotti G.V. et al.: Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26 (21): 3552-3559.
2. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352(9124): 257-263.
3. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al.: Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2012; 30: 172-178.
4. Aupérin A., Le Péchoux C., Rolland E. et al.: Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2010; 28: 2181-2190.
5. Delbaldo C., Michiels S., Syzi N. et al.: Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis. JAMA 2004; 292: 470-484.
6. Boni C., Tiseo M., Boni L. et al.: Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br. J. Cancer 2012; 106: 658-665.
7. Scagliotti G.V., Parikh P., von Pawel J. et al.: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2008; 21: 3543-3551.
8. Jassem J., Biernat W., Drosik K. et al.: Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. Pneumonol. Alergol. Pol. 2010; 78(6): 418-431.
9. Petrelli F., Borgonovo K., Cabiddui M. et al.: Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clin. Lung Cancer 2012; 13: 107-114.
10. Hui G., Xin D., Dong W. et al.: Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2012; 1(2): 129-144.
11. Di Maio M., Chiodini P., Georgoulias V. et al.: Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2009; 27(11): 1836-1843.
12. Online: www.nfz.gov.pl.
2. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352(9124): 257-263.
3. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. et al.: Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2012; 30: 172-178.
4. Aupérin A., Le Péchoux C., Rolland E. et al.: Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2010; 28: 2181-2190.
5. Delbaldo C., Michiels S., Syzi N. et al.: Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis. JAMA 2004; 292: 470-484.
6. Boni C., Tiseo M., Boni L. et al.: Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br. J. Cancer 2012; 106: 658-665.
7. Scagliotti G.V., Parikh P., von Pawel J. et al.: Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2008; 21: 3543-3551.
8. Jassem J., Biernat W., Drosik K. et al.: Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma. Pneumonol. Alergol. Pol. 2010; 78(6): 418-431.
9. Petrelli F., Borgonovo K., Cabiddui M. et al.: Efficacy of EGFR Tyrosine Kinase Inhibitors in Patients With EGFR Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis of 13 Randomized Trials. Clin. Lung Cancer 2012; 13: 107-114.
10. Hui G., Xin D., Dong W. et al.: Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis. Transl. Lung Cancer Res. 2012; 1(2): 129-144.
11. Di Maio M., Chiodini P., Georgoulias V. et al.: Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2009; 27(11): 1836-1843.
12. Online: www.nfz.gov.pl.